Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Peramivir dosing vs oseltamivir in influenza with chronic respiratory disease
jRCTs031180322Completed
- Sponsor
- Shionogi & Co., Ltd.
- Start
- Nov 2017
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Randomised trial of peramivir and oseltamivir in Influenza A infection, influenza B, asthma and 2 more (3 arms), sponsored by Shionogi & Co., Ltd. Primary endpoint: Area under the curve of influenza respiratory symptom score until 2 weeks. Started Nov 2017; status: completed.
02
Drugs
peramiviroseltamivir
03
Conditions
Influenza A infectioninfluenza Basthmachronic obstructive pulmonary disease (COPD)pulmonary fibrosis (PF)
Beyond the preview
Go deeper on jRCTs031180322.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031180322.